REG - AstraZeneca PLC - Jury verdict favours AZ in Nexium litigation <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

05/12/2014 17:10

RNS Number : 0403Z
AstraZeneca PLC
05 December 2014
JURY VERDICT FAVOURS ASTRAZENECA IN 
NEXIUM ANTITRUST LITIGATION
AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy. 
AstraZeneca is pleased with the jury's verdict. The Company has always maintained that the plaintiffs' allegations were without merit.
All parties have appellate rights.
Two cases making similar allegations were filed by numerous purchasers in the state court in Pennsylvania and are still pending.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Jacob Lund +46 8553260 20 (Sweden)
Michele Meixell + 1 302 885 6351 (US)
Investor Enquiries
Thomas Kudsk Larsen +44 20 7604 8199 mob: +44 7818 524185 
Karl Hrd +44 20 7604 8123mob: +44 7789 654364
Eugenia Litz +44 20 7604 8233 mob: +44 7884 735627
Christer Gruvris  +44 20 7604 8126 mob: +44 7827 836825
5 December 2014
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCEAXASEEELFFF